Single dose liposomal Amphotericin and Fluconazole + Fluconazole
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Meningitis
Conditions
Cryptococcal Meningitis
Trial Timeline
Jun 20, 2019 → Apr 1, 2028
NCT ID
NCT03945448About Single dose liposomal Amphotericin and Fluconazole + Fluconazole
Single dose liposomal Amphotericin and Fluconazole + Fluconazole is a phase 2/3 stage product being developed by Gilead Sciences for Cryptococcal Meningitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03945448. Target conditions include Cryptococcal Meningitis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03945448 | Phase 2/3 | Recruiting |
Competing Products
18 competing products in Cryptococcal Meningitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine | Novartis | Phase 2 | 52 |
| Mycograb + placebo | Novartis | Phase 2 | 52 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 76 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| Encochleated Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 69 |